Troy Clifton, MD
Family Medicine · Tifton, GANPI 1114096617
Payments from drug & device makers
Across 209 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$382
- Pfizer$312
- AstraZeneca$296
- Amgen$241
- LEO Pharma Inc.$208
- Boehringer Ingelheim$201
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,306100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $382 |
| Pfizer | 20 | $312 |
| AstraZeneca | 20 | $296 |
| Amgen | 16 | $241 |
| LEO Pharma Inc. | 8 | $208 |
| Boehringer Ingelheim | 12 | $201 |
| Lilly USA, LLC | 17 | $195 |
| Astellas Pharma US Inc | 10 | $172 |
| GSK | 9 | $165 |
| Johnson & Johnson | 11 | $144 |
| AbbVie | 8 | $141 |
| Regeneron Healthcare Solutions, Inc. | 6 | $117 |
| Merck | 8 | $107 |
| Sunovion Pharmaceuticals Inc. | 4 | $71 |
| Bayer | 3 | $56 |
| Sanofi Pasteur Inc. | 4 | $53 |
| Seqirus USA Inc | 3 | $51 |
| Novartis | 2 | $44 |
| Organogenesis Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Grifols USA, LLC | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 2 | $32 |
| Insmed, Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 2 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Almatica Pharma LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Inari Medical, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 2 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Corium, LLC | 1 | $12 |
| Therapeuticsmd, Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Valeritas, Inc. | 1 | $11 |
| Inogen, Inc. | 1 | $8 |
| Ultragenyx Pharmaceutical Inc. | 1 | $7 |
How this compares
$3,307 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 475 | $408,499 |
| TrulicityDulaglutide | 181 | $216,869 |
| EliquisApixaban | 238 | $192,865 |
| FarxigaDapagliflozin Propanediol | 212 | $166,988 |
| OzempicSemaglutide | 168 | $166,903 |
| MounjaroTirzepatide | 108 | $114,068 |
| Humira(Cf) PenAdalimumab | 12 | $83,167 |
| EntrestoSacubitril/Valsartan | 62 | $49,160 |
| MyrbetriqMirabegron | 61 | $38,526 |
| XareltoRivaroxaban | 32 | $31,831 |
| JanuviaSitagliptin Phosphate | 35 | $23,630 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 67 | $20,492 |
| GemtesaVibegron | 28 | $16,187 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 64 | $14,247 |
| Bydureon BciseExenatide Microspheres | 13 | $14,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $201 | $408,499475 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $195 | $335,157305 claims |
| PfizerEliquis | $312 | $192,865238 claims |
| AstraZenecaFarxiga, Symbicort, Nexium | $296 | $174,059240 claims |
| Novo NordiskOzempic | $382 | $166,903168 claims |
| GSKArexvy, Shingrix, Trelegy Ellipta, Arnuity Ellipta | $165 | $50,887165 claims |
| NovartisEntresto | $44 | $49,16062 claims |
| Astellas Pharma US IncMyrbetriq | $172 | $38,52661 claims |
| Johnson & JohnsonXarelto | $144 | $31,83132 claims |
| MerckJanuvia, Janumet Xr | $107 | $29,53746 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $16,18728 claims |
| AbbVieLinzess, Synthroid | $141 | $14,74373 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Tifton
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.